ライフサイエンスコーパス: 13-cis-retinoic acid

1 ective states in humans (FG7142, rimonabant, 13-cis retinoic acid).

2 arrow transplantation (ABMT) with or without 13 cis-retinoic acid.

3 f the type 2 17beta-HSD was not inhibited by 13-cis retinoic acid.

4 and ASCT was performed on day 0, followed by 13-cis-retinoic acid.

5 od stem-cell rescue, local radiotherapy, and 13-cis-retinoic acid.

6 Isotretinoin (13-cis retinoic acid (13-cis RA)) is the most potent inh

7 e of the risk factors for MGD is exposure to 13-cis retinoic acid (13-cis RA), a metabolite of vitami

8 o determine whether combination therapy with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (I

9 tivity in the head and neck and may decrease 13-cis-retinoic acid (13-cRA) toxicity.

10 etinoids, all-trans-retinoic acid (atRA) and 13-cis-retinoic acid (13cisRA), as well as the principal

11 istered as a single agent and in combination 13-cis retinoic acid (13cRA) in children with refractory

12 To conduct a phase III trial of adjuvant 13-cis-retinoic acid (13cRA) plus interferon alfa (IFN-a

13 tudy was to test interferon alfa (IFNalpha), 13-cis-retinoic acid (13cRA), and cisplatin biochemother

14 es treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-

15 ative fluorescence technique, that Accutane (13-cis-retinoic acid), a drug used in the treatment of a

16 We compared these effects with those of 13-cis-retinoic acid, a chemoprevention agent, and with

17 ng the following search terms: isotretinoin, 13-cis-retinoic acid, Accutane, retinoids, acitretin, su

18 ta-apo-12'-carotenal, beta-apo-8'-carotenal, 13-cis-retinoic acid, all-trans-retinoic acid, beta-caro

19 At high concentrations, the combination of 13-cis-retinoic acid and each of the five other drugs re

20 site, achieving mixed clinical results (with 13-cis-retinoic acid and etretinate) in superficial blad

21 at C-4 of all-trans-retinoic acid (ATRA) and 13-cis-retinoic acid, and modification of terminal carbo

22 All-trans-, 9-cis-, and 13-cis-retinoic acid, and the synthetic retinoid Ch55, i

23 f other hydroxylase in response to 9-cis and 13-cis retinoic acid application to adult human skin in

24 ame preparations were unable to use 9-cis or 13-cis retinoic acid as substrate for the hydroxylation

25 chemotherapy, and subsequent treatment with 13-cis-retinoic acid (cis-RA).

26 d the combination of phenylbutyrate (PB) and 13-cis retinoic acid (CRA) as a differentiation and anti

27 Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior

28 A phase I trial of 13-cis-retinoic acid (CRA), IFNalpha, and paclitaxel (TA

29 It was found that all-trans and 13-cis retinoic acids exerted modest, dose-dependent eff

30 receive no further therapy or treatment with 13-cis-retinoic acid for six months.

31 3-0.150 microM); sulindac sulfide, NDGA, and 13-cis-retinoic acid had intermediate potency (IC50 = 4-

32 We found that 13-cis retinoic acid induced, in a concentration-depende

33 in SG homogenates; and (iv) to determine if 13-cis retinoic acid inhibits 17beta-HSD activity.

34 bination of low-dose MK886, ciglitazone, and 13-cis-retinoic acid interacted at least in a superaddit

35 produced by isomerization of both 9-cis and 13-cis retinoic acids is the likely inducer of the 4-hyd

36 Isotretinoin (13-cis retinoic acid) is frequently prescribed for sever

37 of the follicle, or (ii) in the presence of 13-cis-retinoic acid, is due to the reduced expression o

38 13 cis Retinoic acid (isotretinoin) is a retinoid with p

39 alone, and whether subsequent treatment with 13-cis-retinoic acid (isotretinoin) further improves eve

40 Oral 13-cis-retinoic acid maintenance therapy was administere

41 Therapy with 13-cis retinoic acid or low-dose chemotherapy can induce

42 Subsequently, they were randomized to 13-cis-retinoic acid or no further treatment.

43 e have evaluated whether IFN-alpha-2a and/or 13-cis-retinoic acid (RA) enhance radiation cytotoxicity

44 ctive component of the acne drug Accutane is 13-cis-retinoic acid (RA), and it is highly teratogenic

45 nd, and NDGA with paclitaxel, cisplatin, and 13-cis-retinoic acid, regardless of drug-resistance phen

46 everal of these agents (including tamoxifen, 13-cis-retinoic acid, retinyl palmitate, and an acyclic

47 Neither all-trans nor 13-cis retinoic acids s affected cell size as assessed b

48 of other inhibitors such as fenretinide and 13-cis-retinoic acid showed multiple advantages of Ret-N

49 lower levels of all-trans retinoic acid and 13-cis retinoic acid than control subjects but similar 9

50 he 130 patients who were assigned to receive 13-cis-retinoic acid than among the 128 patients assigne

51 tion of 0.1% all-trans, 0.1% 9-cis, and 0.1% 13-cis retinoic acid to human skin for 2 d resulted in i

52 The inability of 9-cis or 13-cis retinoic acid to induce their own hydroxylation a

53 In addition, treatment with 13-cis-retinoic acid was beneficial for patients without

54 Maintenance doses of 13-cis-retinoic acid were then administered until tumor